IPS Stem Cells – Page 76 – Stem Cell Treatments

Category: IPS Stem Cells

Fate Therapeutics Announces Preclinical Data Presentation of Novel CAR MICA/B Cell-based Cancer Immunotherapy Program at the 2020 ASGCT Annual Meeting…

stemadminApril 29, 2020IPS Stem CellsNo comments

Program Incorporates New CAR Constructs Designed to Specifically Target the Pan-tumor Associated Stress Proteins MICA and MICB Proprietary Binding Domains Shown to Overcome MICA/B Shedding, a Common Mechanism of Tumor Cell Escape Broadly Observed Across Solid Tumors Exclusive License Agreement with Dana-Farber Cancer Institute covers MICA/B Binding Domains and iPSC-derived CAR MICA/B Cell Products SAN DIEGO, April 28, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced the presentation of a new off-the-shelf, iPSC-derived, chimeric antigen receptor (CAR)-targeted cell-based cancer immunotherapy program at the American Society of Gene & Cell Therapy (ASGCT) 23rd Annual Meeting to be virtually hosted on May 12 15, 2020. The new preclinical program targets MHC class I related proteins A (MICA) and B (MICB), and is supported by an exclusive license from the Dana-Farber Cancer Institute to intellectual property covering novel antibody fragments binding MICA/B for iPSC-derived cellular therapeutics

Global Cell Culture Market : Industry Analysis and Forecast (2019-2026) – MR Invasion

stemadminApril 29, 2020IPS Stem CellsNo comments

Global Cell Culture Marketwas valued US$ XX Bn in 2018 and is expected to reach US$ XX Bn by 2026, at CAGR of 12% during forecast period. The report study has analyzed revenue impact of covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and same is reflected in our analysis. REQUEST FOR FREE SAMPLE REPORT:https://www.maximizemarketresearch.com/request-sample/33004/ Utilization of cell cultures has improved to an extent where old small-scale production and handling of cultures decreasing for the growing demand.

Diabetes reversed in mice using CRISPR and stem cell therapy – BioNews

stemadminApril 28, 2020IPS Stem CellsNo comments

27 April 2020 Genome-edited human stem cells from diabetic patientshavebeen shown to successfully reverse diabetes in mice. Researchers at Washington University School of Medicine in St Louis, Missouri, used CRISPR/Cas9 to correct a genetic defect in human stem cells and then converted them into cells capable of producing insulin. When these edited insulin-producing cells were implanted into diabetic mice, they were able to effectively control blood sugar levels for six months

Mogrify strikes deal with US biopharma Sangamo Therapeutics – Cambridge Independent

stemadminApril 28, 2020IPS Stem CellsNo comments

Cell conversion specialist Mogrify has announced a collaboration and licence agreement with US genomic medicine company Sangamo Therapeutics.

Citius Announces Pre-IND Submission to FDA Under the Coronavirus Treatment Acceleration Program for a Novel Stem Cell Therapy for Acute Respiratory…

stemadminApril 28, 2020IPS Stem CellsNo comments

CRANFORD, N.J., April 27, 2020 /PRNewswire/ --Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, today announced that it submitted a pre-IND meeting request and supporting briefing documents to the Center for Biologics Evaluation and Research ("CBER") of the FDA under the Coronavirus Treatment Acceleration Program (CTAP) on April 24. The Company has requested the Division's feedback to support the most expeditious pathway into the clinic to evaluate a novel cell therapy in patients suffering from COVID-19-related ARDS.

Mogrify and Sangamo announce collaboration and exclusive license agreement for Mogrifys iPSC- and ESC-derived regulatory T cells – Yahoo Finance

stemadminApril 28, 2020IPS Stem CellsNo comments

Mogrify Ltd (Mogrify), a UK company aiming to transform the development of cell therapies by the systematic discovery of novel cell conversions, and Sangamo Therapeutics (Sangamo) (Nasdaq: SGMO), a genomic medicine company, today announced that they have executed a collaboration and exclusive license agreement for Sangamo to develop allogeneic cell therapies from Mogrifys proprietary induced pluripotent stem cells (iPSCs) and embryonic stem cells (ESCs) and Sangamos zinc finger protein (ZFP) gene-engineered chimeric antigen receptor regulatory T cell (CAR-Treg) technology.

GLOBAL TOOTH REGENERATION MARKET: INDUSTRY ANALYSIS AND FORECAST (2020-2027) – MR Invasion

stemadminApril 28, 2020IPS Stem CellsNo comments

Global Tooth Regeneration Marketwas valued US$ XX Mn in 2019 and is expected to reach US$ XX Mn by 2027, at a CAGR of 6.5% during a forecast period 2020-2027. REQUEST FOR FREE SAMPLE REPORT:https://www.maximizemarketresearch.com/request-sample/55424/ Global Tooth Regeneration Market Market Dynamics The Research Report gives a comprehensive account of the drivers and restraints in the tooth regeneration.Somatic stem cells are composed and reprogrammed to induced pluripotent stem cells which can be placed in the dental lamina directly or placed in an absorbable biopolymer in the shape of the new tooth, which is a main source of the novel bioengineered teeth. Tooth replacement therapy is pondered to be a greatly attractive concept for the next generation bioengineered organ replacement

Induced Pluripotent Stem Cells Market Overview, Top Companies, Region, Application and Global Forecast by 2026 – Latest Herald

stemadminApril 28, 2020IPS Stem CellsNo comments

Reprocell Global Induced Pluripotent Stem Cells Market Segmentation This market was divided into types, applications and regions. The growth of each segment provides an accurate calculation and forecast of sales by type and application in terms of volume and value for the period between 2020 and 2026. This analysis can help you develop your business by targeting niche markets

The integrated stress response: From mechanism to disease – Science Magazine

stemadminApril 24, 2020IPS Stem CellsNo comments

Proteostasis dISRupted Despite their importance, many crucial networks for protein quality control within cells diminish with age. The resulting loss of proteostasis, the process by which the health of a cell's proteins is monitored and maintained, is associated with a wide range of age-related human diseases. Costa-Mattioli and Walter review the integrated stress response (ISR), a central signaling network that responds to proteostasis defects by tuning protein synthesis

Sangamo taps Mogrify for off-the-shelf CAR-Treg project – FierceBiotech

stemadminApril 24, 2020IPS Stem CellsNo comments

Sangamo Therapeutics has struck a deal with Mogrify to gain access to a source of cells for use in its allogeneic CAR-Treg therapies. The agreement sees Sangamo pay an upfront fee to get Mogrify to apply its direct cell conversion technology to the generation of regulatory T cells.